Regarding the problem of viral hepatitis reactivation in rheumatic diseases: risks and curation issues

Infection caused by hepatitis B virus (HBV) remains an important global public health problem with high morbidity and mortality. In modern rheumatology the problem of HBV as a comorbid infection deserves undoubted attention, especially in immune inflammatory rheumatic diseases (IIRD). This fact makes it necessary to modify the treatment tactics of patients receiving modern antirheumatic therapy, including basic anti-inflammatory (BAID) and genetically engineered biological drugs (GEBD). Given the expected further increase in the use of GEBD and new oral targeted BAID (Janus kinase inhibitors) in the treatment of rheumatic diseases, rheumatologists should be aware of the potential risk, recommendations for screening and opportunities for prevention and monitoring of HBV-reactivation (HBV-r). Most of the literature on HBV-r has been obtained from haematology and oncology, which uses combinations of drugs with higher immunosuppressive potential, usually for a short period of time (months). This data should be interpreted with caution in regard to rheumatic diseases, where immunosuppression intensity is lower and therapy duration is longer (several years). In recent years, an attempt has been made to stratify the HBV-r risk according to the patient’s serological status and the type and duration of immunosuppressive treatment used. Based on the above factors, the American Gastroenterological Association has classified the risk of HBV-r as low (<1%), moderate (1-10%) and high (>10%). However, appearance of new drugs and longer duration of their use in rheumatic diseases, wherethere are usually no established timeframes for discontinuation of treatment, require additional explanation of the recommendations on the curation and monitoring of HBV-r. This article presents modern data on HBV-r risk in patients with HBV during treatment with various BAID and GEBD, emphasizes the importance of screening examination for HBV-infection before the planned immunosuppressive therapy and highlights issues related to the tactics of prescribing antiviral prophylaxis and monitoring of these patients condition.

1. Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3(6):383-403. doi: 10.1016/S2468-1253(18)30056-6.

2. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370-398. doi: 10.1016/j.jhep.2017.03.021.

3. Shapiyeva N.T., Ponezheva Zh.B., Makashova V.V., Omarova Kh. G. Modern aspects of chronic hepatitis B. Lechashchiy vrach. 2019;(5). (In Russ.) Available at: https://www.lvrach.ru/2019/05/15437301.

4. Charpin C., Guis S., Colson P., Borentain P., Mattei J.P., Alcaraz P et al. Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients. Arthritis Res Ther. 2009;11(6):R179. doi: 10.1186/ar2868.

5. Kato M., Atsumi T., Kurita T., Odani T., Fujieda Y., Otomo K. et al. Hepatitis B virus reactivation by immunosuppressive therapy in patients with autoimmune diseases: risk analysis in Hepatitis B surface antigen-negative cases. J Rheumatol. 2011;38(10):2209-2214. doi: 10.3899/jrheum.110289.

6. Nakamura J., Nagashima T., Nagatani K., Yoshio T., Iwamoto M., Minota S. et al. Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs. IntJ Rheum Dis. 2016;19(5):470-475. doi: 10.1111/1756-185X.12359.

7. Tien Y.C., Yen H.H., Chiu Y.M. Incidence and clinical characteristics of hepatitis B virus reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for rheumatoid arthritis. Clin Exp Rheumatol. 2017;35(5):831-836. Available at: https://pubmed.ncbi.nlm.nih.gov/28375829.

8. Perrillo R.P., Gish R., Falck-Ytter Y.T. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148(1):221-244.e3. doi: 10.1053/j.gastro.2014.10.038.

9. Koutsianas C., Thomas K., Vassilopoulos D. Reactivation of hepatitis B virus infection in rheumatic diseases: risk and management considerations. TherAdv MusculoskeletDis. 2020;12:1759720X20912646. doi: 10.1177/1759720X20912646.

10. Tur-Kaspa R., Shaul Y, Moore D.D., Burk R.D., Okret S., Poellinger L., Shafritz D.A. The glucocorticoid receptor recognizes a specific nucleotide sequence in hepatitis B virus DNA causing increased activity of the HBV enhancer. Virology. 1988;167(2):630-633.

11. Perrillo R.P., Schiff E.R., Davis G.L., Bodenheimer H.C. Jr., Lindsay K., Payne J. et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med. 1990;323(5):295-301. doi: 10.1056/NEJM199008023230503.

12. Kim T.W., Kim M.N., Kwon J.W., Kim K.M., Kim S.H., Kim W. et al. Risk of hepatitis B virus reactivation in patients with asthma or chronic obstructive pulmonary disease treated with corticosteroids. Respirology. 2010;15(7):1092-1097. doi: 10.1111/j.1440-1843.2010.01798.x.

13. Chen M.H., Chen M.H., Liu C.Y., Tsai C.Y., Huang D.F., Lin H.Y et al. Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Undergoing Biologics Treatment. J Infect Dis. 2017;215(4):566-573. doi: 10.1093/infdis/jiw606.

14. Yang C.H., Wu T.S., Chiu C.T. Chronic hepatitis B reactivation: a word of caution regarding the use of systemic glucocorticosteroid therapy. Br J Dermatol. 2007;157(3):587-590. doi: 10.1111/j.1365-2133.2007.08058.x.

15. Xuan D., Yu Y., Shao L., Wang J., Zhang W., Zou H. Hepatitis reactivation in patients with rheumatic diseases after immunosuppressive therapy - a report of long-term follow-up of serial cases and literature review. Clin Rheumatol. 2014;33(4):577-586. doi: 10.1007/s10067-013-2450-9.

16. Braun-Moscovici Y., Braun M., Saadi T., Markovits D., Nahir M.A., Balbir-Gurman A. Safety of Corticosteroid Treatment in Rheumatologic Patients With Markers of Hepatitis B Viral Infection: Pilot Evaluation Study. J Clin Rheumatol. 2016;22(7):364-368. doi: 10.1097/RHU.0000000000000434.

17. Wong G.L., Wong V.W., Yuen B.W., Tse Y.K., Yip T.C., Luk H.W. et al. Risk of hepatitis B surface antigen seroreversion after corticosteroid treatment in patients with previous hepatitis B virus exposure. J Hepatol. 2020;72(1):57-66. doi: 10.1016/j.jhep.2019.08.023.

18. Hatano M., Mimura T., Shimada A., Noda M., Katayama S. Hepatitis B virus reactivation with corticosteroid therapy in patients with adrenal insufficiency. Endocrinol Diabetes Metab. 2019;2(3):e00071. doi: 10.1002/edm2.71.

19. Di Bisceglie A.M., Lok A.S., Martin P., Terrault N., Perrillo R.P., Hoofnagle J.H. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology. 2015;61(2):703-711. doi: 10.1002/hep.27609.

20. Laohapand C., Arromdee E., Tanwandee T. Long-term use of methotrexate does not result in hepatitis B reactivation in rheumatologic patients. Hepatol Int. 2015;9(2):202-208. doi: 10.1007/s12072-014-9597-6.

21. Tang K.T., Hung W.T., Chen Y.H., Lin C.H., Chen D.Y Methotrexate is not associated with increased liver cirrhosis in a population-based cohort of rheumatoid arthritis patients with chronic hepatitis B. Sci Rep. 2016;6:22387. doi: 10.1038/srep22387.

22. Tan J., Zhou J., Zhao P., Wei J. Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs. Clin Rheumatol. 2012;31(8):1169-1175. doi: 10.1007/s10067-012-1988-2.

23. Fukuda W., Hanyu T., Katayama M., Mizuki S., Okada A., Miyata M. et al. Incidence of hepatitis B virus reactivation in patients with resolved infection on immunosuppressive therapy for rheumatic disease: a multicentre, prospective, observational study in Japan. Ann Rheum Dis. 2017;76(6):1051-1056. doi: 10.1136/annrheumdis-2016-209973.

24. Gong ZJ., De Meyer S., Clarysse C., Verslype C., Neyts J., De Clercq E., Yap S.H. Mycophenolic acid, an immunosuppressive agent, inhibits HBV replication in vitro. J Viral Hepat. 1999;6(3):229-236. doi: 10.1046/j.1365-2893.1999.00163.x.

25. Ying C., De Clercq E., Neyts J. Ribavirin and mycophenolic acid potentiate the activity of guanine- and diaminopurine-based nucleoside analogues against hepatitis B virus. Antiviral Res. 2000;48(2):117-124. doi: 10.1016/s0166-3542(00)00121-2.

26. Maes B.D., van Pelt J.F., Peeters J.C., Nevens F., Evenepoel P., Kuypers D. et al. The effect of mycophenolate mofetil on hepatitis B viral load in stable renal transplant recipients with chronic hepatitis B. Transplantation. 2001;72(6):1165-1166. doi: 10.1097/00007890-200109270-00033.

27. Ben-Ari Z., Zemel R., Tur-Kaspa R. The addition of mycophenolate mofetil for suppressing hepatitis B virus replication in liver recipients who developed lamivudine resistance - no beneficial effect. Transplantation. 2001;71(1):154-156. doi: 10.1097/00007890-200101150-00026.

28. Lin W.T., Chen Y.M., Chen D.Y., Lan J.L., Chang C.S., Yeh H.Z., Yang S.S. Increased risk of hepatitis B virus reactivation in systemic lupus erythematosus patients receiving immunosuppressants: a retrospective cohort study. Lupus. 2018;27(1):66-75. doi: 10.1177/0961203317711009.

29. Schwaneck E.C., Krone M., Kreissl-Kemmer S., WeiEbrich B., Weiss J., Tony H.P. et al. Management of anti-HBc-positive patients with rheumatic diseases treated with disease-modifying antirheumatic drugs-a single-center analysis of 2054 patients. Clin Rheumatol. 2018;37(11):2963-2970. doi: 10.1007/s10067-018-4295-8.

30. Puro R., Schneider RJ.Tumor necrosis factor activates a conserved innate antiviral response to hepatitis B virus that destabilizes nucleocapsids and reduces nuclear viral DNA. J Virol. 2007;81(14):7351-7362. doi: 10.1128/JVI.00554-07.

31. Carroll M.B., Forgione M.A. Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action. Clin Rheumatol. 2010;29(9):1021-1029. doi: 10.1007/s10067-010-1523-2.

32. Vassilopoulos D., Apostolopoulou A., Hadziyannis E., Papatheodoridis G.V, Manolakopoulos S., Koskinas J. et al. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis. 2010;69(7):1352-1355. doi: 10.1136/ard.2009.127233.

33. Perez-Alvarez R., D^az-Lagares C., Garda-Hernandez F., Lopez-Roses L., Brito-Zeron P., Perez-de-Lis M. et al. BIOGEAS Study Group. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore). 2011;90(6):359-371. doi: 10.1097/MD.0b013e3182380a76.

34. Lan J.L., Chen Y.M., Hsieh T.Y., Chen Y.H., Hsieh C.W., Chen D.Y., Yang S.S. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy. Ann Rheum Dis. 2011;70(10):1719-1725. doi: 10.1136/ard.2010.148783.

35. Zingarelli S., Frassi M., Bazzani C., Scarsi M., Puoti M., Airo P Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature. J Rheumatol. 2009;36(6):1188-1194. doi: 10.3899/jrheum.081246.

36. Chung S.J., Kim J.K., Park M.C., Park Y.B., Lee S.K. Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy. J Rheumatol. 2009;36(11):2416-2420. doi: 10.3899/jrheum.081324.

37. Tamori A., Koike T., Goto H., Wakitani S., Tada M., Morikawa H. et al. Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. J Gastroenterol. 2011;46(4):556-564. doi: 10.1007/s00535-010-0367-5.

38. Ye H., Zhang XW., Mu R., Fang L.K., Gu J.R., Lin J. et al. Anti-TNF therapy in patients with HBV infection - analysis of 87 patients with inflammatory arthritis. Clin Rheumatol. 2014;33(1):119-123. doi: 10.1007/s10067-013-2385-1.

39. Koutsianas C., Thomas K., Vassilopoulos D. Hepatitis B Reactivation in Rheumatic Diseases: Screening and Prevention. Rheum Dis Clin North Am. 2017;43(1):133-149. doi: 10.1016/j.rdc.2016.09.012.

40. Mori S. Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs. Mod Rheumatol. 2011;21(6):621-627. doi: 10.1007/s10165-011-0458-z.

41. Caporali R., Bobbio-Pallavicini F., Atzeni F., Sakellariou G., Caprioli M., Montecucco C., Sarzi-Puttini P Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen nega-tive/anti-hepatitis B core antigen positive) with rheumatic diseases. Arthritis Care Res (Hoboken). 2010;62(6):749-754. doi: 10.1002/acr.20130.

42. Lee Y.H., Bae S.C., Song G.G. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy. Clin Exp Rheumatol. 2013;31(1):118-121. Available at: https://pubmed.ncbi.nlm.nih.gov/23111095.

43. Barone M., Notarnicola A., Lopalco G., Viggiani M.T., Sebastiani F., Covelli M. et al. Safety of long-term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection. Hepatology. 2015;62(1):40-46. doi: 10.1002/hep.27716.

44. Tsutsumi Y, Kanamori H., Mori A., Tanaka J., Asaka M., Imamura M., Masauzi N. Reactivation of hepatitis B virus with rituximab. Expert Opin Drug Saf. 2005;4(3):599-608. doi: 10.1517/14740338.4.3.599.

45. Hsu C., Hsiung C.A., Su IJ., Hwang W.S., Wang M.C., Lin S.F. et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin’s lymphoma: a randomized trial. Hepatology 2008;47(3):844-853. doi: 10.1002/hep.22106.

46. Lau G.K., Yiu H.H., Fong D.Y., Cheng H.C., Au W.Y., Lai L.S. et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology. 2003;125(6):1742-1749. doi: 10.1053/j.gastro.2003.09.026.

47. Huang H., Li X., Zhu J., Ye S., Zhang H., Wang W. et al. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial. JAMA. 2014;312(23):2521-2530. doi: 10.1001/jama.2014.15704.

48. Pyrpasopoulou A., Douma S., Vassiliadis T., Chatzimichailidou S., Triantafyllou A., Aslanidis S. Reactivation of chronic hepatitis B virus infection following rituximab administration for rheumatoid arthritis. Rheumatol Int. 2011;31(3):403-404. doi: 10.1007/s00296-009-1202-2.

49. Hui C.K., Cheung W.W., Zhang H.Y., Au W.Y., Yueng Y.H., Leung A.Y et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology. 2006;131(1):59-68. doi: 10.1053/j.gastro.2006.04.015.

50. Seto W.K., Chan T.S., Hwang Y.Y, Wong D.K., Fung J., Liu K.S. et al. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. J Clin Oncol. 2014;32(33):3736-3743. doi: 10.1200/JCO.2014.56.7081.

51. Hsu C., Tsou H.H., Lin SJ., Wang M.C., Yao M., Hwang W.L. et al. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology. 2014;59(6):2092-2100. doi: 10.1002/hep.26718.

52. Koo Y.X., Tay M., Teh Y.E., Teng D., Tan D.S., Tan I.B. et al. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis. Ann Hematol. 2011;90(10):1219-1223. doi: 10.1007/s00277-011-1241-0.

53. Huang Y.H., Hsiao L.T., Hong YC., Chiou TJ., Yu Y.B., Gau J.P. et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol. 2013;31(22):2765-2772. doi: 10.1200/JCO.2012.48.5938.

54. Mitroulis I., Hatzara C., Kandili A., Hadziyannis E., Vassilopoulos D. Longterm safety of rituximab in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis. 2013;72(2):308-310. doi: 10.1136/annrheumdis-2012-202088.

55. van Vollenhoven R.F., Fleischmann R.M., Furst D.E., Lacey S., Lehane P.B. Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years. J Rheumatol. 2015;42(10):1761-1766. doi: 10.3899/jrheum.150051.

56. Varisco V., Vigano M., Batticciotto A., Lampertico P, Marchesoni A., Gibertini P et al. Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc-positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study. J Rheumatol. 2016;43(5):869-874. doi: 10.3899/jrheum.151105.

57. Papalopoulos I., Fanouriakis A., Kougkas N., Flouri I., Sourvinos G., Bertsias G. et al. Liver safety of non-tumour necrosis factor inhibitors in rheumatic patients with past hepatitis B virus infection: an observational, controlled, long-term study. Clin Exp Rheumatol. 2018;36(1):102-109. Available at: https://pubmed.ncbi.nlm.nih.gov/28850029.

58. Tien Y.C., Yen H.H., Chiu Y.M. Incidence and clinical characteristics of hepatitis B virus reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for rheumatoid arthritis. Clin Exp Rheumatol. 2017;35(5):831-836. Available at: https://pubmed.ncbi.nlm.nih.gov/28375829.

59. Chen Y.M., Yang S.S., Chen D.Y Risk-stratified management strategies for HBV reactivation in RA patients receiving biological and targeted therapy: A narrative review. J Microbiol Immunol Infect. 2019;52(1):1-8. doi: 10.1016/j.jmii.2017.10.002.

60. Mok C.C. Hepatitis B and C infection in patients undergoing biologic and targeted therapies for rheumatic diseases. Best Pract Res Clin Rheumatol. 2018;32(6):767-780. doi: 10.1016/j.berh.2019.03.008.

61. Kim P.S., Ho G.Y., Prete P.E., Furst D.E. Safety and efficacy of abatacept in eight rheumatoid arthritis patients with chronic hepatitis B. Arthritis Care Res (Hoboken). 2012;64(8):1265-1268. doi: 10.1002/acr.21654.

62. Padovan M., Filippini M., Tincani A., Lanciano E., Bruschi E., Epis O. et al. Safety of Abatacept in Rheumatoid Arthritis With Serologic Evidence of Past or Present Hepatitis B Virus Infection. Arthritis Care Res (Hoboken). 2016;68(6):738-743. doi: 10.1002/acr.22786.

63. Nagashima T., Minota S. Long-term tocilizumab therapy in a patient with rheumatoid arthritis and chronic hepatitis B. Rheumatology (Oxford). 2008;47(12):1838-1840. doi: 10.1093/rheumatology/ken384.

64. Tsuboi H., Tsujii A., Nampei A., Yoshihara H., Kawano K., Takeuchi E., Shi K. A patient with rheumatoid arthritis treated with tocilizumab together with lamivudine prophylaxis after remission of infliximab-reactivated hepatitis B. Mod Rheumatol. 2011;21(6):701-705. doi: 10.1007/s10165-011-0470-3.

65. Kishida D., Okuda Y., Onishi M., Takebayashi M., Matoba K., Jouyama K. et al. Successful tocilizumab treatment in a patient with adult-onset Still’s disease complicated by chronic active hepatitis B and amyloid A amyloidosis. Mod Rheumatol. 2011;21(2):215-218. doi: 10.1007/s10165-010-0365-8.

66. Chen L.F., Mo Y.Q., Jing J., Ma J.D., Zheng D.H., Dai L. Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation. Int J Rheum Dis. 2017;20(7):859-869. doi: 10.1111/1756-185X.13010.

67. Ahn S.S., Jung S.M., Song JJ., Park Y.B., Park J.Y., Lee S.W. Safety of Tocilizumab in Rheumatoid Arthritis Patients with Resolved Hepatitis B Virus Infection: Data from Real-World Experience. Yonsei Med J. 2018;59(3):452-456. doi: 10.3349/ymj.2018.59.3.452.

68. Nakamura J., Nagashima T., Nagatani K., Yoshio T., Iwamoto M., Minota S. Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs. Int J Rheum Dis. 2016;19(5):470-475. doi: 10.1111/1756-185X.12359.

69. Chiu H.Y., Hui R.C., Huang Y.H., Huang R.Y., Chen K.L., Tsai Y.C. et al. Safety Profile of Secukinumab in Treatment of Patients with Psoriasis and Concurrent Hepatitis B or C: A Multicentric Prospective Cohort Study. Acta Derm Venereol. 2018;98(9):829-834. doi: 10.2340/00015555-2989.

70. Chiu H.Y, Chen C.H., Wu M.S., Cheng Y.P., Tsai T.F. The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C. Br J Dermatol. 2013;169(6):1295-1303. doi: 10.1111/bjd.12461.

71. Ting S.W., Chen Y.C., Huang Y.H. Risk of Hepatitis B Reactivation in Patients with Psoriasis on Ustekinumab. Clin Drug Investig. 2018;38(9):873-880. doi: 10.1007/s40261-018-0671-z.

72. Chen Y.M., Huang W.N., Wu Y.D., Lin C.T., Chen Y.H., Chen D.Y. et al. Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib: a real-world study. Ann Rheum Dis. 2018;77(5):780-782. doi: 10.1136/annrheumdis-2017-211322.

73. Harigai M., Winthrop K., Takeuchi T., Hsieh T.Y., Chen Y.M., Smolen J.S. et al. Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis. RMD Open. 2020;6(1):e001095. doi: 10.1136/rmdo-pen-2019-001095.

74. Terrault N.A., Lok A.S.F., McMahon BJ., Chang K.M., Hwang J.P., Jonas M.M. et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560-1599. doi: 10.1002/hep.29800.

75. Hwang J.P, Lok A.S. Management of patients with hepatitis B who require immunosuppressive therapy. Nat Rev Gastroenterol Hepatol. 2014;11(4):209-219. doi: 10.1038/nrgastro.2013.216.